메뉴 건너뛰기




Volumn 4, Issue 11, 2015, Pages

PCSK9 inhibition: Does lipoprotein size matter?

Author keywords

Diabetes mellitus; Editorials; Lipids and lipoproteins; Low density lipoprotein cholesterol; Low density lipoprotein particles; Metabolic syndrome; Monoclonal antibodies; PCSK9

Indexed keywords

ALIROCUMAB; ATORVASTATIN; CHOLESTEROL; EVOLOCUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

EID: 85006226017     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002806     Document Type: Editorial
Times cited : (1)

References (18)
  • 1
    • 79952515201 scopus 로고    scopus 로고
    • Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
    • Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5:105-113.
    • (2011) J Clin Lipidol , vol.5 , pp. 105-113
    • Otvos, J.D.1    Mora, S.2    Shalaurova, I.3    Greenland, P.4    Mackey, R.H.5    Goff, D.C.6
  • 2
    • 84874949110 scopus 로고    scopus 로고
    • Update on the detection and treatment of atherogenic low-density lipoproteins
    • Sniderman A, Kwiterovich PO. Update on the detection and treatment of atherogenic low-density lipoproteins. Curr Opin Endocrinol Diabetes Obes. 2013;20:140-147.
    • (2013) Curr Opin Endocrinol Diabetes Obes , vol.20 , pp. 140-147
    • Sniderman, A.1    Kwiterovich, P.O.2
  • 6
    • 33645103550 scopus 로고    scopus 로고
    • Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    • Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
    • (2006) N Engl J Med , vol.354 , pp. 1264-1272
    • Cohen, J.C.1    Boerwinkle, E.2    Mosley, T.H.3    Hobbs, H.H.4
  • 7
    • 84942104125 scopus 로고    scopus 로고
    • PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
    • Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36:2415-2424.
    • (2015) Eur Heart J , vol.36 , pp. 2415-2424
    • Shimada, Y.J.1    Cannon, C.P.2
  • 9
    • 85006201116 scopus 로고    scopus 로고
    • Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy
    • Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM. Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. J Am Heart Assoc. 2015;4:e002224 doi: 10.1161/JAHA.115.002224.
    • (2015) J Am Heart Assoc , vol.4
    • Koren, M.J.1    Kereiakes, D.2    Pourfarzib, R.3    Winegar, D.4    Banerjee, P.5    Hamon, S.6    Hanotin, C.7    McKenney, J.M.8
  • 10
    • 84862219022 scopus 로고    scopus 로고
    • Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy
    • McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-2353.
    • (2012) J Am Coll Cardiol , vol.59 , pp. 2344-2353
    • McKenney, J.M.1    Koren, M.J.2    Kereiakes, D.J.3    Hanotin, C.4    Ferrand, A.C.5    Stein, E.A.6
  • 11
    • 84976897420 scopus 로고    scopus 로고
    • Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
    • Xu RX, Li S, Zhang Y, Li XL, Guo YL, Zhu CG, Li JJ. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids Health Dis. 2014;13:188.
    • (2014) Lipids Health Dis , vol.13 , pp. 188
    • Xu, R.X.1    Li, S.2    Zhang, Y.3    Li, X.L.4    Guo, Y.L.5    Zhu, C.G.6    Li, J.J.7
  • 12
    • 84939424952 scopus 로고    scopus 로고
    • Lipoprotein particle subclass profiles among metabolically healthy and unhealthy obese and non-obese adults: does size matter?
    • Phillips CM, Perry IJ. Lipoprotein particle subclass profiles among metabolically healthy and unhealthy obese and non-obese adults: does size matter? Atherosclerosis. 2015;242:399-406.
    • (2015) Atherosclerosis , vol.242 , pp. 399-406
    • Phillips, C.M.1    Perry, I.J.2
  • 14
    • 35848940724 scopus 로고    scopus 로고
    • The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes
    • Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes. 2007;115:477-482.
    • (2007) Exp Clin Endocrinol Diabetes , vol.115 , pp. 477-482
    • Rizzo, M.1    Rini, G.B.2    Berneis, K.3
  • 15
    • 84864270750 scopus 로고    scopus 로고
    • Extendedrelease niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus
    • Bays H, Giezek H, McKenney JM, O'Neill EA, Tershakovec AM. Extendedrelease niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metab Syndr Relat Disord. 2012;10:260-266.
    • (2012) Metab Syndr Relat Disord , vol.10 , pp. 260-266
    • Bays, H.1    Giezek, H.2    McKenney, J.M.3    O'Neill, E.A.4    Tershakovec, A.M.5
  • 17
    • 77955046691 scopus 로고    scopus 로고
    • Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients
    • Chan DC, Hamilton SJ, Rye KA, Chew GT, Jenkins AJ, Lambert G, Watts GF. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab. 2010;12:752-756.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 752-756
    • Chan, D.C.1    Hamilton, S.J.2    Rye, K.A.3    Chew, G.T.4    Jenkins, A.J.5    Lambert, G.6    Watts, G.F.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.